T Gerhard1, K Huybrechts1, M Olfson1, S Schneeweiss1, W V Bobo1, P M Doraiswamy1, D P Devanand1, J A Lucas1, C Huang1, E S Malka1, R Levin1, S Crystal1. 1. Tobias Gerhard, PhD, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, and Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey; Krista Huybrechts, PhD, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Mark Olfson, MD MPH, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York, New York; Sebastian Schneeweiss, MD, ScD, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; William V. Bobo, MD, Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, Tennessee; P. Murali Doraiswamy, MD, Department of Psychiatry, Duke University Medical Center, Durham, North Carolina; D. P. Devanand, MD, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and the New York State Psychiatric Institute, New York, New York; Judith A. Lucas, EdD RN, Cecilia Huang, PhD, Edmond S. Malka, PhD, MPH, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey; Raisa Levin, MS, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Stephen Crystal, PhD, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, New Jersey, USA.
Abstract
BACKGROUND: All antipsychotic medications carry warnings of increased mortality for older adults, but little is known about comparative mortality risks between individual agents. AIMS: To estimate the comparative mortality risks of commonly prescribed antipsychotic agents in older people living in the community. METHOD: A retrospective, claims-based cohort study was conducted of people over 65 years old living in the community who had been newly prescribed risperidone, olanzapine, quetiapine, haloperidol, aripiprazole or ziprasidone (n = 136 393). Propensity score-adjusted Cox proportional hazards models assessed the 180-day mortality risk of each antipsychotic compared with risperidone. RESULTS: Risperidone, olanzapine and haloperidol showed a dose-response relation in mortality risk. After controlling for propensity score and dose, mortality risk was found to be increased for haloperidol (hazard ratio (HR) = 1.18, 95% CI 1.06-1.33) and decreased for quetiapine (HR = 0.81, 95% CI 0.73-0.89) and olanzapine (HR = 0.82, 95% CI 0.74-0.90). CONCLUSIONS: Significant variation in mortality risk across commonly prescribed antipsychotics suggests that antipsychotic selection and dosing may affect survival of older people living in the community. Royal College of Psychiatrists.
BACKGROUND: All antipsychotic medications carry warnings of increased mortality for older adults, but little is known about comparative mortality risks between individual agents. AIMS: To estimate the comparative mortality risks of commonly prescribed antipsychotic agents in older people living in the community. METHOD: A retrospective, claims-based cohort study was conducted of people over 65 years old living in the community who had been newly prescribed risperidone, olanzapine, quetiapine, haloperidol, aripiprazole or ziprasidone (n = 136 393). Propensity score-adjusted Cox proportional hazards models assessed the 180-day mortality risk of each antipsychotic compared with risperidone. RESULTS:Risperidone, olanzapine and haloperidol showed a dose-response relation in mortality risk. After controlling for propensity score and dose, mortality risk was found to be increased for haloperidol (hazard ratio (HR) = 1.18, 95% CI 1.06-1.33) and decreased for quetiapine (HR = 0.81, 95% CI 0.73-0.89) and olanzapine (HR = 0.82, 95% CI 0.74-0.90). CONCLUSIONS: Significant variation in mortality risk across commonly prescribed antipsychotics suggests that antipsychotic selection and dosing may affect survival of older people living in the community. Royal College of Psychiatrists.
Authors: Donovan T Maust; Hyungjin Myra Kim; Lisa S Seyfried; Claire Chiang; Janet Kavanagh; Lon S Schneider; Helen C Kales Journal: JAMA Psychiatry Date: 2015-05 Impact factor: 21.596
Authors: Dae Hyun Kim; Mufaddal Mahesri; Brian T Bateman; Krista F Huybrechts; Sharon K Inouye; Edward R Marcantonio; Shoshana J Herzig; E Wesley Ely; Margaret A Pisani; Raisa Levin; Jerry Avorn Journal: J Am Geriatr Soc Date: 2018-08-19 Impact factor: 5.562
Authors: Ryan M Silwanowicz; Donovan T Maust; Lisa S Seyfried; Claire Chiang; Claire Stano; Helen C Kales Journal: Int J Geriatr Psychiatry Date: 2016-10-04 Impact factor: 3.485
Authors: Inken Arnold; Kati Straube; Wolfgang Himmel; Stephanie Heinemann; Vivien Weiss; Laura Heyden; Eva Hummers-Pradier; Roland Nau Journal: BMC Pharmacol Toxicol Date: 2017-12-04 Impact factor: 2.483
Authors: Yoonyoung Park; Brian T Bateman; Dae Hyun Kim; Sonia Hernandez-Diaz; Elisabetta Patorno; Robert J Glynn; Helen Mogun; Krista F Huybrechts Journal: BMJ Date: 2018-03-28